|
|
Blood, 1 June 2006, Vol. 107, No. 11, pp. 4300-4307.
Prepublished online as a Blood First Edition Paper on February 16, 2006; DOI 10.1182/blood-2005-11-4433.
Previous Article | Table of Contents | Next Article 
HEMATOPOIESIS
A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis
Takanori Nakamura,
Yoshitaka Miyakawa,
Atsushi Miyamura,
Akiko Yamane,
Hidenori Suzuki,
Mamoru Ito,
Yasuyuki Ohnishi,
Norihisa Ishiwata,
Yasuo Ikeda, and
Nobutomo Tsuruzoe
From the Pharmaceutical Research Department, Biological Research Laboratories, Nissan Chemical Industries, Saitama; Department of Internal Medicine, Keio University School of Medicine, Tokyo; Medical Research & Development Center, Tokyo Metropolitan Institute of Medical Science, Tokyo; and Central Institute for Experimental Animals, Kanagawa, Japan.
NIP-004 is a novel synthetic compound developed to display human thrombopoietin (TPO) receptor (c-Mpl) agonist activity. NIP-004 displays species specificity, stimulating proliferation or differentiation of human c-Mplexpressing cells such as UT-7/TPO and human CD34+ cells but not murine c-Mplexpressing cells or cynomolgus monkey cells. To test the mechanism of its action, we constructed mutant forms of c-Mpl; murine c-MplL490H dis-played a response to NIP-004, whereas human c-MplH499L lost this response, indicating that histidine in the transmembrane domain of c-Mpl is essential for its activity. Because histidine is not present in the c-Mpl transmembrane domain of rats, hamsters, rhesus macaques, and cynomolgus monkeys, we examined the in vivo efficacy of NIP-004 using mice that received xenotransplants. In immunodeficient nonobese diabetic (NOD)/Shi-scid, IL-2R null (NOG) mice receiving transplants of umbilical cord bloodderived CD34+ cells, NIP-004 increased human megakaryoblasts, mature megakaryocytes, and circulating human platelets 6-fold, the latter being morphologically and functionally indistinguishable from normal human platelets. These observations indicate that NIP-004 is a novel human c-Mpl activator and induces human thrombopoiesis.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
W. Nogami, H. Yoshida, K. Koizumi, H. Yamada, K. Abe, A. Arimura, N. Yamane, K. Takahashi, A. Yamane, A. Oda, et al.
The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis
Haematologica,
October 1, 2008;
93(10):
1495 - 1504.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Yamane, T. Nakamura, H. Suzuki, M. Ito, Y. Ohnishi, Y. Ikeda, and Y. Miyakawa
Interferon-{alpha}2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes
Blood,
August 1, 2008;
112(3):
542 - 550.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Jenkins, D. Williams, Y. Deng, J. Uhl, V. Kitchen, D. Collins, and C. L. Erickson-Miller
Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist
Blood,
June 1, 2007;
109(11):
4739 - 4741.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M.-J. Kim, S. H. Park, S. J. Opella, T. H. Marsilje, P.-Y. Michellys, H. M. Seidel, and S.-S. Tian
NMR Structural Studies of Interactions of a Small, Nonpeptidyl Tpo Mimic with the Thrombopoietin Receptor Extracellular Juxtamembrane and Transmembrane Domains
J. Biol. Chem.,
May 11, 2007;
282(19):
14253 - 14261.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Andemariam, B. Psaila, and J. B. Bussel
Novel Thrombopoietic Agents
Hematology,
January 1, 2007;
2007(1):
106 - 113.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|